Drugs / AKR 202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02003118 | Oct 2013 → Jul 2014 | osteoarthritis | Akron Molecules AG | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKR 202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02003118 ↗ |